La Jolla Pharmaceutical (LJPC) Reports Q2 Loss of $0.70/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
- SanDisk upgraded at JPMorgan after investor day; shares climb
La Jolla Pharmaceutical (LJPC) Announces FDA Acceptance of LJPC-401 IND
August 11, 2015 8:03 AM EDTLa Jolla Pharmaceutical (NASDAQ: LJPC) announced that the U.S. Food and Drug Administration (FDA) has accepted the Companys Investigational New Drug Application (IND) for LJPC-401, La Jollas novel formulation of hepcidin. La Jolla expects to release preliminary results from a Phase 1 clinical trial of LJPC-401 by the end of 2015.
Hepcidin is a naturally occurring regulator of iron... More
